|Articles|March 1, 1996

Calcium Channel Blockers: 1995 -- The Year in Review
Volume 2
Issue 4 Suppl

Participants

Download PDF: Participants

Articles in this issue

over 30 years ago

Article

Calcium Channel Blockers: 1995 - An Overview

over 30 years ago

Article

Safety of Calcium Channel Blockers: Results of Recent Trials

over 30 years ago

Article

Calcium Channel Blockers: New Trials and Trials in Progress

over 30 years ago

Article

Are Calcium Channel Blockers Prohemorrhagic?

over 30 years ago

Article

A Provocative Interpretation of the Case Control Analysis

over 30 years ago

Article

Update - January 1996: FDA Does Not Support Labeling Changes to Calcium Antagonists Other Than Immediate-Release Nifedipine

over 30 years ago

Article

Shades of Opinion: What Is Prudent?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

Medicaid, health insurance | Image credit: Tada Images - stock.adobe.com

October 22nd, 2026

Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts

Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.

Bronchiectasis. | Image credit: @Bronchiectasis.jpeg

October 21st, 2026

Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

FDA approval | Image Credit: Surendra - stock.adobe.com

October 21st, 2026

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

Oxygen mask of nebulizer - elif - stock.adobe.com

October 21st, 2026

Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

pill with water | Image credit: New Africa - stock.adobe.com

October 21st, 2026

Real-World Trial Shows Oral Alitretinoin Effective for Severe Hand Eczema

A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.

San Diego Skyline | Image Credit: © f11photo-stock.adobe.com

October 21st, 2026

Managed Care Keeps Pace With Policy as AMCP Nexus Heads to San Diego

AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg

October 21st, 2026

Subset of Patients Hospitalized With cUTI May Qualify for Outpatient Care

IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.

Raymond L. Benza, MD | Image credit: Mount Sinai

October 20th, 2026

Extension Studies in TPIP Show Promise in PAH, PH-ILD

Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.

Participants

Articles in this issue

Related to this article

Trending on AJMC

Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD

Extension Studies in TPIP Show Promise in PAH, PH-ILD

International Panel Agrees on Framework for Tapering Psoriasis Biologics

Bepirovirsen Approval Offers New Option for Chronic HBV Treatment

ETI Improves Outcomes in Children With CF, Most in F508del Homozygotes